Novartis Receives EU Marketing Authorization for Diovan

June 13, 2005

Novartis announced that it has successfully completed an EU type 2 variation procedure in 14 countries for Diovan (valsartan) for the treatment of people with heart failure. Diovan, a powerful antihypertensive agent, is now indicated as a potentially life-saving therapy for people with symptomatic heart failure when an ACE inhibitor cannot be used, or as add-on therapy to ACE inhibitors when beta blockers can not be used. Diovan provides a new treatment option for the more than 4.5 million people with heart failure in the countries that are covered by this variation procedure.

PharmaLive (http://www.pharmalive.com/News/index.cfm?articleid=247693&categoryid=29)